iSpecimen Inc. Cost of Revenue
iSpecimen Inc. (ISPC) reported Cost of Revenue of $1.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-04-01
- iSpecimen Inc. cost of revenue for the quarter ending 2025-12-31 was $550.95K, a 56.83% decline year-over-year.
- iSpecimen Inc. cost of revenue for the quarter ending 2025-09-30 was $156.70K, a 89.60% decline year-over-year.
- iSpecimen Inc. cost of revenue for the quarter ending 2025-06-30 was $396.29K, a 71.21% decline year-over-year.
- iSpecimen Inc. cost of revenue for the quarter ending 2025-03-31 was $609.39K, a 36.00% decline year-over-year.
- iSpecimen Inc. cost of revenue for fiscal 2025 was $1.71M, a 66.48% decline from fiscal 2024.
- iSpecimen Inc. cost of revenue for fiscal 2024 was $5.11M, a 7.14% increase from fiscal 2023.
- iSpecimen Inc. cost of revenue for fiscal 2023 was $4.77M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $550.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $707.65K derived: sum of 2 quarters · filed 2026-04-01 | $1.10M derived: sum of 3 quarters · filed 2026-04-01 | $1.71M 10-K · filed 2026-04-01 |
| 2025-09-30 | $156.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $552.99K derived: sum of 2 quarters · filed 2025-11-17 | $1.16M 10-Q · filed 2025-11-17 | $2.44M derived: sum of 4 quarters · filed 2026-04-01 |
| 2025-06-30 | $396.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.01M 10-Q · filed 2025-08-14 | $2.28M derived: sum of 3 quarters · filed 2026-04-01 | $3.79M derived: sum of 4 quarters · filed 2026-04-01 |
| 2025-03-31 | $609.39K 10-Q · filed 2025-05-19 | $1.89M derived: sum of 2 quarters · filed 2026-04-01 | $3.39M derived: sum of 3 quarters · filed 2026-04-01 | $4.77M derived: sum of 4 quarters · filed 2026-04-01 |
| 2024-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $2.78M derived: sum of 2 quarters · filed 2026-04-01 | $4.16M derived: sum of 3 quarters · filed 2026-04-01 | $5.11M 10-K · filed 2026-04-01 |
| 2024-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $2.88M derived: sum of 2 quarters · filed 2025-11-17 | $3.83M 10-Q · filed 2025-11-17 | |
| 2024-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.33M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $952.12K 10-Q · filed 2025-05-19 | |||
| 2023-12-31 | $4.77M 10-K · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |